Literature DB >> 11005561

Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group.

H J Nielsen1, I J Christensen, S Sørensen, F Moesgaard, N Brünner.   

Abstract

BACKGROUND: Preoperative plasma plasminogen activator inhibitor-1 (PAI-1) is a prognostic variable in patients with colorectal cancer. It has been suggested, however, that plasma PAI-1 is a nonspecific prognostic parameter similar to the acute-phase reactant C-reactive protein (CRP). In the present study we analyzed the association between plasma PAI-1 and serum CRP in patients scheduled for elective resection of colorectal cancer. In addition, the prognostic value of PAI-1 and CRP was studied in this patient cohort.
METHODS: PAI-1 and CRP were analyzed in citrated plasma and serum, respectively, obtained preoperatively from 594 patients. Patients who required preoperative blood transfusion received SAGM blood, in which soluble PAI-1 is not present. None of the patients received pre- or postoperative adjuvant chemotherapy, and all were followed in the outpatient clinic for at least 5 years or until death. The association of PAI-1 and CRP, respectively, with survival was tested using the median value of PAI-1 and the upper normal limit for CRP. Analyses were performed by inclusion of all patients, and in the subgroup of patients, who underwent curative resection.
RESULTS: The median follow-up period was 6.8 (5.4-7.9) years. The median value of plasma PAI-1 was 35.8 ng/ml, and values greater than 94 nmol/L identified patients with increased CRP levels. Comparison of the molecules showed that PAI-1 was weakly correlated with CRP (r = .26; P <.0001). Both molecules showed a Dukes independent distribution. In univariate survival analyses high levels of PAI-1 were found associated with poor prognosis and low levels with good prognosis (P = .02, HR: 1.3). Similarly, high levels of CRP were found associated with poor prognosis and low levels with good prognosis (P <.0001, HR: 1.9). In a multivariate statistical analysis including Dukes classification, gender, age, tumor location, perioperative blood transfusion, PAI-1 and CRP, plasma PAI-1 was a dependent prognostic variable, while serum CRP (P <.0001; HR: 1.4; 95% CI: 1.3-1.5) was found to be a Dukes independent prognostic variable. Similar analyses, excluding patients with Dukes' D disease showed serum CRP to be an independent prognostic variable (P <.0001; HR: 1.3: 95% CI: 1.2-1.5).
CONCLUSIONS: This study did not show a strong correlation between plasma PAI-1 and serum CRP in patients with colorectal cancer. Serum CRP was found to be a Dukes independent prognostic variable in this patient cohort, and was found to identify a subgroup of curatively resected patients at risk for short survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005561     DOI: 10.1007/bf02725342

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  45 in total

1.  Influence of major surgery on the mannan-binding lectin pathway of innate immunity.

Authors:  H Ytting; I J Christensen; L Basse; J Lykke; S Thiel; J C Jensenius; H J Nielsen
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  Influence of anastomotic leakage on oncological outcome in patients with rectal cancer.

Authors:  In Ja Park
Journal:  J Gastrointest Surg       Date:  2010-01-22       Impact factor: 3.452

3.  Prognostic value of the combination of pre- and postoperative C-reactive protein in colorectal cancer patients.

Authors:  Manabu Yamamoto; Hiroaki Saito; Chihiro Uejima; Akimitsu Tanio; Seigo Takaya; Teruhisa Sakamoto; Soichiro Honjo; Yoshihiko Maeta; Keigo Ashida; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2018-06-26       Impact factor: 2.549

4.  Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer.

Authors:  Donald C McMillan; Joseph E M Crozier; Khalid Canna; Wilson J Angerson; Colin S McArdle
Journal:  Int J Colorectal Dis       Date:  2007-01-24       Impact factor: 2.571

5.  Prognostic significance of platelet × C-reactive protein multiplier in patients with esophageal squamous cell carcinoma.

Authors:  Yuji Shishido; Hiroaki Saito; Shota Shimizu; Yusuke Kono; Yuki Murakami; Kozo Miyatani; Tomoyuki Matsunaga; Manabu Yamamoto; Yoji Fukumoto; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2019-08-30       Impact factor: 2.549

6.  A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.

Authors:  Kenneth H Minor; Christine R Schar; Grant E Blouse; Joseph D Shore; Daniel A Lawrence; Peter Schuck; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2005-05-19       Impact factor: 5.157

7.  Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Eiji Noda; Hiroshi Ohtani; Yukio Nishiguchi; Kosei Hirakawa
Journal:  Surg Today       Date:  2014-05-10       Impact factor: 2.549

8.  Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.

Authors:  Lisa Pleyer; Philip Went; Gudrun Russ; Erika Prinz; Viktoria Faber; Hans-Joachim Röwert; Renate Karlbauer; Richard Greil
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

9.  Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer.

Authors:  Konstantinos K Tsilidis; Kathy J Helzlsouer; Michael W Smith; Victoriya Grinberg; Judith Hoffman-Bolton; Sandra L Clipp; Kala Visvanathan; Elizabeth A Platz
Journal:  Cancer Causes Control       Date:  2009-11       Impact factor: 2.506

10.  The relationship between deprivation, tumour stage and the systemic inflammatory response in patients with primary operable breast cancer.

Authors:  A M Al Murri; J C Doughty; A Lannigan; C Wilson; C S McArdle; D C McMillan
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.